[Effect of Cynaropicrin on 2,3,4,7,8-Pentachlorodibenzofuran-induced Wasting Syndrome and Oxidative Stress]. 2015

Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada

The effect of cynaropicrin that is the major component of an edible plant, artichoke (Cynara scolymus) on 2,3,4,7,8-pentachlorodibenzofuran (PenCDF)-induced toxicity in mice was studied. We evaluated the effect of cynaropicrin on the wasting syndrome and oxidative stress elicited by PenCDF. However, the PenCDF dose-response relationship on the wasting syndrome has been superficial. Therefore, we determined the dose which causes wasting syndrome in C57BL/6J mice, a responsive strain to dioxins. Since 2,3,7,8-tetrachlorodibenzo-p-dioxin (0.1 mg/kg, p.o.) induces hepatic ethoxyresorfin O-deethylase (EROD) activity in mice, we set the doses of PenCDF at 0.3, 1.0, 3.0, 5.0 and 10 mg/kg (once, p.o.) on the basis of its toxic-eqivalency factor (0.3). The wasting syndrome was evaluated by measuring the daily changes of body weight. Thiobarbituric acid-reactive substances were used as an index of oxidative stress. Of PenCDF doses examined, wasting syndrome and oxidative stress took place most markedly in 5 mg/kg. In disagreement with this, EROD activity which is the marker of the aryl hydrocarbon receptor-dependent induction of cytochrome P450 1a1 was elevated most abundantly at 0.3 mg/kg. Then, we examined the effect of cynaropicrin on the wasting syndrome and oxidative stress provoked by PenCDF at 5 mg/kg. However, this compound up to 20 mg/kg (p.o.) did not attenuate PenCDF-induced wasting syndrome. On the contray, PenCDF-induced oxidateive stress was suppressed by cynaropicrin at the highest dose (20 mg/kg), although EROD activity was increased rather than reduced by cynaropicrin at lower doses. Thus, it is suggested that cynaropicrin has an ability to reduce oxidative stress caused by PenCDF.

UI MeSH Term Description Entries
D007783 Lactones Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactone
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001572 Benzofurans Compounds that contain a BENZENE ring fused to a furan ring. Coumarones,Diphenylbenzofuran
D012717 Sesquiterpenes Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24. Farnesanes,Farnesene,Farnesenes,Sesquiterpene,Sesquiterpene Derivatives,Sesquiterpenoid,Sesquiterpenoids,Derivatives, Sesquiterpene
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018384 Oxidative Stress A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi). Anti-oxidative Stress,Antioxidative Stress,DNA Oxidative Damage,Nitro-Oxidative Stress,Oxidative Cleavage,Oxidative DNA Damage,Oxidative Damage,Oxidative Injury,Oxidative Nitrative Stress,Oxidative Stress Injury,Oxidative and Nitrosative Stress,Stress, Oxidative,Anti oxidative Stress,Anti-oxidative Stresses,Antioxidative Stresses,Cleavage, Oxidative,DNA Damage, Oxidative,DNA Oxidative Damages,Damage, DNA Oxidative,Damage, Oxidative,Damage, Oxidative DNA,Injury, Oxidative,Injury, Oxidative Stress,Nitrative Stress, Oxidative,Nitro Oxidative Stress,Nitro-Oxidative Stresses,Oxidative Cleavages,Oxidative DNA Damages,Oxidative Damage, DNA,Oxidative Damages,Oxidative Injuries,Oxidative Nitrative Stresses,Oxidative Stress Injuries,Oxidative Stresses,Stress Injury, Oxidative,Stress, Anti-oxidative,Stress, Antioxidative,Stress, Nitro-Oxidative,Stress, Oxidative Nitrative,Stresses, Nitro-Oxidative
D019282 Wasting Syndrome A condition of involuntary weight loss of greater then 10% of baseline body weight. It is characterized by atrophy of muscles and depletion of lean body mass. Wasting is a sign of MALNUTRITION as a result of inadequate dietary intake, malabsorption, or hypermetabolism. Wasting Disease,Wasting Diseases,Wasting Syndromes

Related Publications

Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
May 1983, Fukuoka igaku zasshi = Hukuoka acta medica,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
December 1986, Cancer letters,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
May 1989, Fukuoka igaku zasshi = Hukuoka acta medica,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
September 1987, Toxicology and applied pharmacology,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
June 2002, Journal of toxicology and environmental health. Part A,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
May 1985, Fukuoka igaku zasshi = Hukuoka acta medica,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
June 1984, Journal of pharmacobio-dynamics,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
February 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
May 1989, Fukuoka igaku zasshi = Hukuoka acta medica,
Ken-ichi Yamada, and Yuji Ishii, and Tomoki Takeda, and Hiroaki Kuroki, and Chikage Mitoma, and Hiroshi Uchi, and Masutaka Furue, and Hideyuki Yamada
April 2012, Biochimica et biophysica acta,
Copied contents to your clipboard!